Jump to content

Xtandi (enzalutamide) Phase III trial starts today for non-metastatic castrate resistant prostate cancer, including Australia


Recommended Posts

Jim Marshall (not a doctor) said ...


A Phase 3 Study of Xtandi (Enzalutamide) in Non-Metastatic Castration-Resistant Prostate Cancer enrolled its first subject today.


Australia is included in the countries where this trial (PROSPER) are offered.


We will let you have more information when it is to hand.


In the meantime, if you have rising PSA while castrate resistant (low testosterone), ask your doctor about this.


Trials of drugs that people expect will be good tend to fill quickly.

... end Jim


Click the following line for the press release:


Phase 3 Study of Enzalutamide in Non-Metastatic Castration-Resistant Prostate Cancer

Link to comment
Share on other sites


This topic is now archived and is closed to further replies.

  • Create New...